AFC
BMRN icon

Ares Financial Consulting’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ares Financial Consulting’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4K Hold
70
– – ﹤0.01% 767
2026
Q1 		$4.01K Buy
+70
New +$4.08K ﹤0.01% 725

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Ares Financial Consulting's BMRN Position: Q2 2026 in Review

Ares Financial Consulting held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 70 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Ares Financial Consulting first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.01K in Q1 2026. 228 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Ares Financial Consulting held 70 shares of BioMarin Pharmaceuticals worth $4K as of Q2 2026.
  • Ares Financial Consulting left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #767 holding.
  • Ares Financial Consulting first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Ares Financial Consulting's BioMarin Pharmaceuticals position peaked at $4.01K in Q1 2026.
  • 228 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.